GovChime
Notice ID: c1c30163deaa45378a8434d6020f5ff4Combined Synopsis/Solicitation

Drug Database Licensing

Archived on June 22, 2022. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
11:00 AM UTC−04:00
Posted
May 27, 2022
Notice type
Combined Synopsis/Solicitation
NAICS
511199: Classification Not Available
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NLM
Place of performance
Bethesda, MD, 20892
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75N97022Q00034
Notice ID
c1c30163deaa45378a8434d6020f5ff4

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the procedures contained in FAR Part 12.6, Acquisition of Commercial Items, and FAR Part 13, Simplified Acquisition Procedures, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. This acquisition is for the selected contractor to provide drug database licensing. (A) The solicitation number is 75N97022Q00034 and is issued as a Request for Quotation (RFQ). (B) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-05. (C) The associated NAICS code is 511199 and the size standard in number of employees is 500. (D) List CLINS, item descriptions, quantities and units of measure: See attached RFQ. (E) Description/Statement of Work/Specification: See attached RFQ. (F) FAR Provision 52.212-1, Instructions to Offerors-Commercial, is incorporated by reference and applies to this acquisition. Please see the attached RFQ terms and conditions for the submission requirements. (G) FAR Provision 52.212-2, Evaluation Commercial Products and Commercial Services, is incorporated by reference and applies to this acquisition. For the evaluation criteria, please see the attached RFQ terms and conditions. (H) Offerors are required to complete in full FAR Provision 52.212-3, Offeror Representations and Certifications-Commercial Items, with their offer online at SAM: www.sam.gov. An offeror must state in their offer if they completed FAR 52.212-3 online and that is it up-to-date and valid. See the attached RFQ terms and conditions for more requirements. (I) FAR Clause 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. Please see the attached RFQ terms and conditions for its Addendum. (J) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, is incorporated and applies to this acquisition. Please see the attached RFQ terms and conditions that are applicable to the acquisition. (K) A statement regarding any additional contract requirement(s) or terms and conditions (such as contract financing arrangements or warranty requirements) determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices: N/A. (L) Date, time and place offers are due. Offers are due by June 7th, 2022 at 11:00 AM EST. Submit offers to the following e-mail address(es), by the offer due date and time: Cameron Earle Cameron.earle@nih.gov and Karen Miller Karen.miller@nih.gov.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75N97022Q00034
  1. Combined Synopsis
  1. Combined SynopsisCurrentMay 27, 2022

    Drug Database Licensing

    Notice c1c30163deaa45378a8434d6020f5ff4 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75N97022Q00034

Archive Date

Jun 22, 2022

Office Address

BETHESDA, MD, 20892